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Novel classes of small and long non-coding RNAs (ncRNAs) are increasingly becoming
apparent, being engaged in diverse structural, functional and regulatory activities. They
take part in target gene silencing, play roles in transcriptional, post-transcriptional and
epigenetic processes, such as chromatin remodeling, nuclear reorganization with the
formation of silent compartments and fine-tuning of gene recruitment into them. Among
their functions, non-coding RNAs are thought to act either as guide or scaffold for
epigenetic modifiers that write, erase, and read the epigenetic signature over the genome.
Studies on human disorders caused by defects in epigenetic modifiers and involving
neurological phenotypes highlight the disruption of diverse classes of non-coding RNAs.
Noteworthy, these molecules mediate a wide spectrum of neuronal functions, including
brain development, and synaptic plasticity. These findings imply a significant contribution
of ncRNAs in pathophysiology of the aforesaid diseases and provide new concepts for
potential therapeutic applications.
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INTRODUCTION
Our common view of the complexity of mammalian tran-
scriptome has been revolutionized by the advent in the high-
throughput sequencing highlighting that tens of thousands of
sites produce transcripts with tiny protein-coding potential.
Indeed, it is now increasingly clear that the vast majority of the
genome is transcribed in both sense and antisense directions and
this transcription is active in a cell context- and a developmen-
tal stage-specific way. Moreover, a rigorous distinction between
protein-coding and non-coding transcripts is misleading, consid-
ering that some non-coding RNAs (ncRNAs) can be translated
and other RNA transcripts may participate in regulatory and
functional processes, rather than serving simply as intermediates
for translation.
NcRNAs are commonly classified based on their size in
two major groups: small ncRNA (sncRNAs, 20-30nt) which
are involved in post-transcriptional regulation of target RNAs
via RNAi, and/or modifying other RNAs, including microRNAs
(miRNAs), Piwi-interacting RNAs (piRNAs) and small nucleolar
RNAs (snoRNAs), and the heterogeneous group of long ncRNAs
(lncRNAs, >200nt), such as transcribed ultraconserved regions
(T-UCRs) and large intergenic ncRNAs (lincRNAs) (Figure 1).
MiRNAs are a class of small ncRNA with a role in post-
transcriptional gene regulation through the base-pairing with the
3′-UTR of the target transcript. This interaction leads to degrada-
tion of the target or to inhibition of translation (Kim et al., 2009).
siRNAs and piRNAs are small ncRNAs generated through the pro-
cessing of LINE-1 and other retrotransposons, being involved in
the silencing of repetitive elements (Saxena et al., 2012).
LncRNAs have roles in transcriptional and epigenetic regula-
tion by recruiting transcription factors and chromatin-modifying
complexes to specific nuclear and genomic sites (Khalil et al.,
2009); in alternative splicing and other post-transcriptional RNA
modifications through the assembly of nuclear domains contain-
ing RNA-processing factors (Wang and Chang, 2011; Caudron-
Herger and Rippe, 2012). The emerging structural and functional
activities of lncRNAs were categorized within a well-designed
framework as molecules of signals, decoys, guides, and scaffolds
(Wang and Chang, 2011).
NON-CODING RNAs IN NEURONAL FUNCTIONS
NcRNAs are involved inmediating a broad spectrum of biological
processes especially those occurring in the central nervous system,
where neural cells are highly expressing diverse classes of ncRNAs.
Indeed, ncRNAs provide neural cells with the ability to precisely
control the spatio-temporal expression of genes, which is a crit-
ical aspect for fulfilling complex neurobiological processes. The
newest finding that in neural tissue mRNAs express significantly
longer 3′UTRs, compared to other tissues, provides intriguing
mechanisms for cell type-specific regulations that are governed
by miRNAs, RNA-binding proteins and ribonucleoprotein aggre-
gates (Wang and Yi, 2014).
For instance, various miRNAs show selective expression or
are particularly abundant in brain (Kosik, 2006). Indeed, DICER
ablation in mouse cerebral cortex, interrupting the biogenesis of
all miRNAs, reduces the cortical size, by decreasing neural stem
cell and neural progenitor pool, increasing apoptosis and affecting
neuronal differentiation, whereas its ablation in postmitotic neu-
rons in the cortex and hippocampus results in smaller cortex and
increased cell death (Bian and Sun, 2011). Specific miRNAs have
been implicated in neuronal differentiation and maintenance of
neuronal phenotype (Im and Kenny, 2012), being integrated with
the circuitry of CREB, repressor-element-1 (RE1)-silencing tran-
scription factor REST and REST-corepressor 1 (CoREST), which
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FIGURE 1 | Non-coding RNAs: biogenesis and their relation to
chromatin disorders. (A) MicroRNAs originate as primary miRNA
(pri-miRNAs) that are processed by the DROSHA/PASHA complex in the
nucleus. The resulting precursor miRNAs (pre-miRNAs) are exported into
the cytoplasm, where they are processed by DICER1 to form mature
miRNAs, which interact with RNA-induced silencing complex (RISC),
acquiring a post-transcriptional silencing activity (B) Long non-coding RNA
are heterogeneous transcripts, often longer than 2 kb, transcribed from
intra- and intergenic regions by RNApol-II and, rarely, RNApol-III (C) Small
nucleolar RNAs (snoRNAs) are codified primarily from introns. After the
pre-mRNA generation, the transcript is spliced and the intron lariat is
debranched and trimmed. The mature snoRNA interacts with ribonuclear
proteins (RNPs), before being exported into the cytoplasm with a role in
ribosomal RNA (rRNA) modification and processing, or retained into the
nucleus, where it plays a role in alternative splicing and other unknown
functions (D) In mouse, promoter-RNAs (pRNAs) are generated from
intergenic regions located around 2 kb upstream to the pre-rRNA
transcriptional start site. They are processed in molecules of 150–250
nucleotides and are thought to form a DNA:RNA triplex at the promoter,
from which they are transcribed (E) Long interspersed nuclear elements-1
(LINE-1 or L1s) are retrotransposons dispersed throughout the genome
that can be transcribed and inserted as extracopies of themselves (F)
Piwi-interacting RNA (piRNA) originates as precursors from transposons
and large piRNA clusters, then they are processed and exported into
cytoplasm, where they undergo a primary or cyclic secondary processing
(ping pong cycle, mediated by PIWI, MIWI, and MIWI2 proteins in mouse)
and the assembly in piRNP complexes that modulate transposon activity
and gene expression (G) Telomeric repeat-containing RNA (TERRA) is a
large non-coding RNA transcribed from chromosome ends directly involved
in the telomeric heterochromatin organization and preservation of telomere
length. An up-to-date summary of the diverse class of ncRNAs, which
have been functionally associated to Rett Syndrome and ICF Syndrome, as
well as to the imprinting disease Prader-Willy/Angelman and
Beckwith–Wiedemann syndromes, is reported in the table.
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are master transcriptional and epigenetic regulators of neural
genes and neural cell fate decisions (Qureshi and Mehler, 2012).
While most efforts have been devoted in identifying the neuro-
biological functions of miRNA, studies characterizing the expres-
sion and function of other classes of small and long ncRNAs in
the central nervous system has begun to emerge. For instance, a
specific set of piRNAs is highly expressed in the hippocampus,
where they might play a role in spine morphogenesis (Lee et al.,
2011). LncRNAs are also likely to have important roles in shap-
ing brain development (Mercer et al., 2008; Ponjavic et al., 2009).
A functional study examined the chromatin-state signature of
neural progenitor cells (NPCs) identifying around one thousand
lincRNAs, with some of them associated with hippocampal devel-
opment, oligodendrocytes maturation and GABAergic-neuronal
function (Guttman et al., 2009). A large percentage of these lincR-
NAs are involved in recruiting chromatin-modifying complexes
to their genomic target sites, serving as scaffolds to specify the pat-
tern of histonemodifications (Tsai et al., 2010).Moreover,MeCP2
physically associates with RNCR3 (retinal non-coding RNA 3),
unveiling new mechanisms of MeCP2/lncRNAs-mediated chro-
matin remodeling (Maxwell et al., 2013).
These observations provide insight into the complex interplay
between ncRNAs and multifunctional epigenetic and transcrip-
tional regulatory complexes coordinating neuronal lineage spec-
ification. In line with that, it is expected that if these ncRNAs
regulate the development and maintenance of healthy neurons,
their dysfunction may contribute to neurodevelopmental abnor-
malities (Qureshi and Mehler, 2012).
Here, we focused on the latest findings linking ncR-
NAs into the molecular and neural phenotypical defects of
human disorders with deficiencies in (i) epigenetic modifiers,
like MeCP2 (methyl-CpG-binding-protein-2) for the Rett syn-
drome (RTT) and DNMT3B (DNA-methyltrasferase-3B) for the
Immumodeficiency, Centromeric instability, Facial anomalies
(ICF) syndrome (Type1) or (ii) in the establishment of DNA
methylation signature, as for the imprinting disorders (Figure 1).
Mutations in MeCP2 gene are linked to the severe postnatal
neurodevelopmental disorder RTT syndrome, the second most
common cause of mental retardation in females. It is char-
acterized by developmental stagnation and regression, loss of
purposeful hand movements and speech, stereotypic hand move-
ments, deceleration of brain growth, autonomic dysfunction and
seizures (Chahrour and Zoghbi, 2007). The ICF syndrome is
caused by genetic defects in the catalytic activity of DNMT3B pro-
tein leading to genomic DNA hypomethylation and heterochro-
matin defects (Matarazzo et al., 2009). Beside immunological
abnormalities, patients exhibit from mild to severe mental retar-
dation and neurologic problems, including slow cognitive and
motor development and psychomotor impairment (Ehrlich et al.,
2006).
Defective inheritance of the imprinted signature is the
main cause of the Prader–Willi (PWS) Angelman (AS) and
Beckwith–Wiedemann syndromes (BWS). Both AS and PWS
show learning dysfunctions and behavioral defects. Mutations
or loss of the maternally-expressed gene UBE3A are responsi-
ble for AS, whereas loss of paternally-expressed genes, proba-
bly including SNRPN, causes PWS. BWS is caused by altered
expression of imprinted genes belonging to a gene cluster at
11p15.5, and patients exhibits neurodevelopmental defects (Kent
et al., 2008).
NON-CODING RNAs AS TRANSCRIPTIONAL AND
POST-TRANSCRIPTIONAL REGULATORS
RTT is primarily caused by mutations in MECP2 gene, codi-
fying a protein involved in both transcriptional repression and
activation. Mecp2-null mice show many neurological symptoms
recapitulating RTT (Della Ragione et al., 2012). Until recently,
the classical approach to search for MeCP2 target genes involved
in Rett pathogenesis was focused on protein-coding RNA tran-
scripts. However, recent findings suggest a role of MeCP2 in
transcriptional regulation of different classes of ncRNAs.
In 2010, two different large-scale analyses highlighted global
dysregulation ofmiRNAs inMeCP2-null mice.Wu and colleagues
identified several up- and down-regulated miRNAs in cerebella of
Mecp2-deficient mice and, for many of them a direct promoter
binding of MeCP2 was demonstrated. Interestingly, MeCP2 reg-
ulates the expression of a large cluster of miRNAs embedded
within the Dlk1-Gtl2 imprinting domain, showing different lev-
els of deregulation, suggesting the existence of miRNA-specific
posttranscriptional regulation. Remarkably, MeCP2 silences miR-
30a/d, miR-381 andmiR-495, which in turn repress Brain-derived
neurotrophic factor (BDNF), the down-regulated target gene in
Mecp2-null mice (Wang et al., 2006); this suggests a multilayered
MeCP2-mediated transcriptional regulation of BDNF (Wu et al.,
2010).
Similarly, microarray expression analysis of Mecp2-null brains
revealed alterations of several miRNAs. Noteworthy, deregulated
miR-29 and miR-146 are known to have roles in neural and glial
cells and its association with neurological disorders is reported
(Urdinguio et al., 2007).
Although the classical form of RTT is associated with loss-of-
function MECP2 mutations, duplication of this gene is respon-
sible for RTT-like neurological phenotypes (Del Gaudio et al.,
2006); therefore, a fine-tuning of MeCP2 level might be impor-
tant for normal development.
In the last years, some reports highlighted a miRNAs con-
tribution to maintain the correct levels of MeCP2. In rat neu-
rons homeostatic mechanisms regulate MeCP2 levels through the
stimulation of BDNF expression, which in turn induces miR132,
thereby silencing MeCP2 expression (Klein et al., 2007). Later,
it was shown that miR-212, located in the same cluster of miR-
132, also targets MeCP2 and that MeCP2 silences the expression
of both miRNAs, confirming the existence of a similar negative
homeostatic feed-back loop between MeCP2 and mir-212, (Im
et al., 2010).
Although several works highlighted a role of MeCP2 in tran-
scriptional regulation of miRNAs, its involvement in the control
of lncRNAs was poorly investigated. In Mecp2-deficient cerebella
increased levels of Gtl2/MEG3, an imprinted ncRNA specifi-
cally expressed from maternal allele has been described. MeCP2-
direct binding to the differentially methylated region controlling
maternal specific expression was reported, suggesting a role of
MeCP2 in the repression of paternal allele in the cerebellum
(Jordan et al., 2007).
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Very recently, the comparison of MeCP2-null and wt mouse
brains transcriptome profiles highlighted 701 deregulated lncR-
NAs. Among lncRNAs with neuronal functions, the authors
validated the up-regulation of AK081227 and AK087060, whose
promoter is directly bound to MeCP2 in wt. Interestingly, the
up-regulation of AK087060 is associated with an overexpression
of the host gene, Arhgef26, codifying a Rho-guanin-nucleotide-
exchange-factor (GEF) involved in neuronal functions, whereas
the up-regulation of AK081227 is associated to a down-regulation
of its host gene, the GABA-receptor-subunit-rho-2 (Gabrr2).
Noteworthy, the GABAergic inhibitory neurotransmission is
impaired in RTT (Coghlan et al., 2012). These findings indicate
that lncRNAs deregulation in a MeCP2-deficient context may
contribute to the RTT pathophysiology providing evidence for
disrupted cis-regulated mechanisms in the disorder (Petazzi et al.,
2013).
Recently, a functional link between ncRNAs, MeCP2 and
GABAergic interneuron development has been found. Embryonic
ventral forebrain-2 (Evf2) lncRNA is transcribed from the con-
served Dlx-5/6 intergenic enhancer and regulates Dlx5 and Dlx6
expression during forebrain development by trans- and cis-acting
mechanisms, respectively. It was shown that Evf2 recruits both
DLX2 (activator) and MeCP2 (repressor) on the same ultracon-
served Dlx5/6 enhancers in order to balance the correct expres-
sion of Dlx5 and Dlx6 during brain development. Remarkably,
Evf2 loss causes GABAergic interneurons decrease in develop-
ing hippocampus. GABA-dependent inhibitory cortical activity
is impaired in RTT-mice, thus MeCP2 and Evf2 loss may share
common mechanisms (Bond et al., 2009). More recently, it is
shown that MeCP2 represses Evf2 and Dlx5, whose expression is
stimulated by DLX1/2 and that Evf2 prevents the DNA methyla-
tion of Dlx5/6 enhancer regardless MeCP2 (Berghoff et al., 2013).
Altogether, these results suggest that ncRNAs deregulation may
contribute to RTT pathoetiology.
While MECP2 reads and interprets the epigenetic signature,
the de novo DNMT3B is the epigenetic factor establishing it
during development.
Mutations interfering with its catalytic activity are known
to affect the transcriptional profile of several hundred protein-
coding genes in ICF patients’ derived cells, with enriched func-
tional classes including development and neurogenesis (Jin et al.,
2008). Most of them do not exhibit promoter methylation defects,
meaning that they are indirectly affected by DNMT3B deficiency
(Matarazzo et al., 2004). Interestingly, a significant proportion
of these genes are target of miRNAs, which are inversely deregu-
lated in ICF-derived cells, suggesting that miRNAs are integrated
in the DNMT3B-mediated regulatory circuitry modulating cell-
specific gene expression program (Gatto et al., 2010). MiR-338
is the most up-regulated miRNAs with brain-specific functions,
while among the down-regulated miRNAs, miR-196a is tran-
scribed from intergenic regions within Hox genes clusters in
vertebrates. As for the Hox genes, miR-196a acts as regulators
of the nervous system development in embryos (Kosik, 2006).
Intriguingly, LHX2, which is crucial for the proper development
of cerebral cortex in mouse embryo is a miR-196a target gene,
and results overexpressed in DNMT3B-deficient cells (Gatto et al.,
2010).
Beyond the pivotal role of DNA methylation in miRNAs
transcriptional control, there are examples describing the effect
of ncRNAs on the epigenetic machinery and the DNMTs. The
finding that a promoter-associated RNA recruits DNMT3B,
inducing the methylation and the following repression of ribo-
somal RNA genes (rDNA) reveals a fascinating mechanism
of RNA-dependent DNA methylation in mammals (Schmitz
et al., 2010). Interestingly, DNMT3B exhibits binding specificity
for a DNA:RNA-triplex, which are structures contributing to
promoter-specific transcriptional repression by compromising
transcription factor binding. That raises the exciting possibility
that triplex-dependent recruitment of DNMT3B to specific genes
might be a common function of regulatory ncRNAs.
Ribosomal RNAs are the target of another class of ncRNAs,
the small nucleolar RNAs. Thesemolecules are intermediate-sized
ncRNAs (60–300 nt) predominantly intronic, which might be
exported for processing the ribosomal RNA and/or remain in the
nucleus for alternative splicing of mRNAs through yet unknown
mechanisms.
They have been found playing an important role in imprinting
disorders, specifically those with a neurodevelopmental compo-
nent, such as PWS and AS. They are caused by several genetic and
epigenetic mechanisms involving the 15q11–q13 imprinted locus,
which contains a cluster of tandemly-arranged snoRNAs (Sahoo
et al., 2008). Loss of the snoRNA HBII-52 has been associated to
PWS, in which it regulates the alternative splicing of the sero-
tonin receptor HTR2C precursor mRNA, resulting in a protein
with reduced function. Additional snoRNAs at 15q11.2, including
the Snord116 cluster, are even more likely candidates for causing
PWS (Duker et al., 2010).
The PWS imprinting-control region contains multiple
neuron-specific ncRNAs, including the antisense transcript
to AS-causing ubiquitin-ligase Ube3a (Ube3a-ATS) (Meng
et al., 2012). Neuron-specific transcriptional progression through
Ube3a-ATS correlates with paternal Ube3a silencing. Intriguingly,
topoisomerase inhibitors represses Ube3a-ATS inducing forma-
tion of DNA:RNA hybrids (R-loops), thus reverting the paternal
allele silencing and providing a means to compensate for the loss
of maternal Ube3a in AS patients (Powell et al., 2013).
Beckwith-Wiedemann (BWS) syndrome is also associated with
altered expression of imprinted genes at 11p15.5. In particu-
lar, BWS results from increased expression of the paternally-
expressed growth promoter IGF2 and/or reduced expression (or
loss of function) of the maternal growth suppressor CDKN1C.
An intragenic miRNA of the imprinted IGF2 (miR-483-5p) reg-
ulates MeCP2 levels through a human-specific binding site in the
MECP2 long 3′-UTR. There is an inverse correlation of miR-483-
5p and MeCP2 levels in developing human brains and fibroblasts
from BWS patients. Importantly, the expression of miR-483-5p
rescues abnormal dendritic spine phenotype of neurons overex-
pressing MeCP2.
LncRNA appear to play a key role in the BWS pheno-
type. KCNQ1OT1 is paternally transcribed from the imprinted-
domain-2 of chromosome 11p15.5 (Weksberg et al., 2001). In
the majority of BWS, loss of maternal methylation at IC2 is
associated with bi-allelic transcription of the KCNQ1OT1 mater-
nal allele (Choufani et al., 2013) and the bi-allelic silencing of
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the imprinted-domain genes, including the cell growth inhibitor
CDKN1C (Diaz-Meyer et al., 2003). Notably, CDKN1C loss-
of-function causes the typical overgrowth and increased risk to
develop embryonic tumor in BWS patients.
NON-CODING RNAs AND TRANSCRIPTIONAL CONTROL OF
REPEATS AND HETEROCHROMATIN
Recent reports highlighted a widespread misregulation of repeat-
elements in Mecp2-deficient contexts. In rodents, MeCP2 loss is
responsible for alteration of LINE1 neuronal transcription and
retrotransposition (Muotri et al., 2010). An increased activity of
L1 promoter in mouse Mecp2-null NPCs correlates to increased
transcription. Noteworthy, increased L1 retrotransposition was
also observed in NPCs generated from RTT patients induced
pluripotent stem cells (iPSCs) and in postmortem brains from
RTT patients. Therefore, MeCP2 seems to control L1 mobility in
the nervous system and the absence of a functional protein may
deregulate the retrotransposition with potential consequences for
RTT (Muotri et al., 2010).
Further evidences onMeCP2-mediated regulation of repetitive
elements showed that L1 retrotransposons, intracisternal-A-
particles (IAP) and the major-satellite are up-regulated inMecp2-
null brains. These findings suggest thatMeCP2may act as a global
regulator, probably by suppressing the spurious transcription of
repetitive elements, thereby reducing the transcriptional noise
(Skene et al., 2010).
LINE1 processing originates small ncRNAs including piR-
NAs, with a function related to the retrotransposons silencing.
Therefore, it can be supposed that in a context of LINE1 excess,
piRNAs may be also deregulated. The level of piRNAs in wt and
Mecp2-null mouse cerebella by Wu et al. (2010) has been exam-
ined, finding 357 piRNAs expressed in wt cerebellum, the 59%
of them showing a marked up-regulation in Mecp2-null mice.
Intriguingly, the DQ541777 piRNA, important for the dendritic
spine size that is impaired in Rett syndrome, is also overexpressed
in Mecp2-null mice. In this light, it was proposed a model in
which, in the absence of functional MeCP2 the overexpression
of LINE-1 may lead to an increase in the piRNAs levels affecting
the expression of specific genes deregulated in RTT (Saxena et al.,
2012).
An important process in which the epigenetic players MeCP2
and DNMT3B interact with ncRNAs is the maintenance of the
integrity at telomeric heterochromatin to prevent the telom-
ere shortening (Deng et al., 2010). Telomeric-repeat-containing-
RNAs (TERRAs) are lncRNAs transcribed from telomeres,
involved in the formation of telomeric heterochromatin through
a negative-feedback looping mechanism. TERRAs interact with
several heterochromatin-associated proteins, including MeCP2,
HP1, and H3K9 methyltrasferase. This interaction may be suf-
ficient to nucleate heterochromatin complexes; the recruitment
of DNMT3B and the establishment of CpG methylation at sub-
telomeres likely mediate this process. Indeed, in ICF-derived-cells
TERRA levels are abnormally increased and telomeres are abnor-
mally shortened (Yehezkel et al., 2008). The proposed mechanism
implies that loss of CpG methylation at subtelomeres due to
DNMT3B mutations results in a failure of TERRA-mediated
feedback-looping. This allows for transcription factors to access
to subtelomeres leading to a permissive chromatin state. Highly
induced TERRA levels may contribute to telomere dysfunction
in ICF cells either by inhibiting telomerase activity, forming
RNA-DNAs hybrids with telomeres, or by interactions with
telomere-binding proteins (Deng et al., 2010). The latest live
imaging-based model, in which TERRA sequesters and deliv-
ers telomerase to the chromosome end from which the tran-
script originated, support the first mechanism (Cusanelli et al.,
2013).
Genome-wide studies have reported an extensive reduction
of DNA methylation at several repeat families, with satellite and
transposons revealing the highest reduction. That implies the
DNMT3B activity as crucial for centromere stability and trans-
poson repression (Heyn et al., 2012). Overexpression of satellite
II and satellite α DNA at pericentromeric and centromeric het-
erochromatin respectively has been indeed reported (Alexiadis
et al., 2007), which might be functionally involved in the chro-
mosomal aberrations in ICF syndrome.
CONCLUSIONS
Increasing reports highlighting aberrant regulation of different
classes of ncRNAs in chromatin disorders characterized by neu-
rological defects, open new perspectives for the comprehension
of the pathogenetic mechanism of these disorders. These mis-
regulated ncRNAs may be identified as responsible for specific
subset of complex phenotypes, providing us with valuable means
to the development of more effective therapeutic strategies based
on RNA regulators.
Experimental approaches using high-throughput chemical
screens are being proved to be suitable to find molecules that
can both activate or inhibit the RNAi/miRNA pathway and,
potentially correct some neurological defects (Li et al., 2010).
Therapeutic strategies based on the design of specific oligonu-
cleotides targeting ncRNAs, with the aim to specifically silence
or replace the transcript, are being explored (Esteller, 2011) and
appear very promising. However, their selective delivery into the
CNS remains the most considerable challenge, and until now it
has not been addressed effectively.
Noteworthy, recent reports indicated that miRNA expres-
sion profile in peripheral blood samples mirror the one present
in the brain after cerebral ischaemia subsequent to stroke
(Tan et al., 2009). In addition, neural cells can release ncR-
NAs in the blood and cerebrospinal fluid in membrane-
bound exosomes (Skog et al., 2008). These evidences suggest
that ncRNAs from body fluids might be used as biomark-
ers of neurological diseases. Further efforts are needed to
decipher the intricate ncRNA world, and help to clarify
how deregulation of ncRNAs may contribute to neuronal
dysfunctions.
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